Connecting clinical care, data and research
PartnershipsContact
← Back to publications

RESEARCH PUBLICATION / 2025

Original Article

SGLT2 inhibitors and COPD acute exacerbations and death

SGLT-2 Inhibitors and the Risk of Chronic Obstructive Pulmonary Disease Exacerbations and Mortality in Chronic Obstructive Pulmonary Disease Patients.

Annals of the American Thoracic Society

Citation & Authors

Ann Am Thorac Soc. 2025;22(6):846-854.

Fu-Shun Yen; James Cheng-Chung Wei; Yu-Han Huang; Tzu-Ju Hsu; Sing-Ting Wang; Chii-Min Hwu; Chih-Cheng Hsu

ABSTRACT · RESEARCH SUMMARY

Research summary

Using Taiwanese National Health Insurance data, the study matched 1,288 pairs of patients with diabetes and COPD. SGLT2 inhibitors were associated with a lower risk of the composite of COPD hospitalization, ventilation, or death (aHR 0.79; 95% CI 0.67–0.93). Noninvasive ventilation, COPD hospitalization, and death were also less frequent. The findings support further evaluation of their role in this comorbid population.

Key points based on the public abstract; this is a reading guide, not a full abstract translation.Read original abstract ↗